Engaging Innovation | Friends of Cancer Research

Engaging Innovation

Featured Post

November 20, 2019

Friends Of Cancer Research Annual Meeting 2019

The Friends of Cancer Research (Friends) Annual Meeting 2019 began with welcoming remarks by Ellen Sigal, Chairperson & Founder of Friends, and Jeff Allen, President & CEO of Friends. In her remarks, Sigal emphasized the time and effort spent by working group members on putting together collaborative whitepapers meant to...
More Posts

Recent Posts

No Results With Current Filter Choices

Designing the Future of Cell Therapies

“Patients are waiting. These therapies are potentially curative. They’re important for the field.” - Ellen Sigal   On May 17, 2019, Friends of Cancer Research (Friends) and the Parker Institute for Cancer Immunotherapy (PICI) held a public meeting on “Designing the Future of Cell Therapies” to explore forward-looking opportunities in the cell...

Data Driven: How Oncologists Perceive FDA-Approved Drug Labeling Compared to Other Major Prescribing Resources

Physicians rely on a variety of sources of information to provide high-quality care to patients. In oncology, some of the most prominent resources that inform provider decision-making are the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) clinical practice guidelines; drug compendia; electronic point-of-care decision...

Data Driven: Molecular Diagnostic Testing in Lung Cancer

Molecular diagnostics are central to the delivery of personalized cancer care. Without these important tools, physicians would not be able to select the appropriate patients for targeted therapy, negating the advantages conferred by recent advances in genomics. In the past fifteen years, there has been an explosion of new technologies to...

Data Driven: US Regulatory System Leads the World in New Drug Review Times

In the second installment of Data Driven, Friends of Cancer Research explores President Trump's claim that FDA's drug regulation impedes timely access to new medicines. We compared the time the FDA takes to review new cancer drugs with the time it takes European regulators to accomplish the same task.

Data Driven: Mining ClinicalTrials.gov – Institutions, Funding, and Areas of Focus

We thought it would be interesting to explore data from agencies whose work most closely impacts biomedical innovation, namely the National Institutes of Health (NIH), the Food and Drug Administration (FDA), and the Centers for Medicare and Medicaid Services (CMS). In the first of a series, Friends investigated the NIH-sponsored site ClinicalTrials.gov. 

My Story: Stephanie Haney

Stephanie and her family were shocked by her diagnosis. She had no risk factors or family history. With the help of newly available treatments, such as breakthrough therapies, she has defied the odds.

My Story: Stephanie Haney

Stephanie and her family were shocked by her diagnosis. She had no risk factors or family history. With the help of newly available treatments, such as breakthrough therapies, she has defied the odds.

Back to Top